Spero Therapeutics Q4 2023 GAAP EPS $0.96 Beats $(0.10) Estimate, Sales $73.524M Beat $18.633M Estimate
Spero Therapeutics Q4 2023 GAAP EPS $0.96 Beats $(0.10) Estimate, Sales $73.524M Beat $18.633M Estimate
Spero Therapeutics 2023年第四季度GAAP每股收益为0.96美元，超过预期（0.10美元），销售额为7,352.4万美元超过预期的1,8633万美元
Spero Therapeutics (NASDAQ:SPRO) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $(0.10) by 1060 percent. This is a 74.55 percent increase over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $73.524 million which beat the analyst consensus estimate of $18.633 million by 294.58 percent. This is a 54.98 percent increase over sales of $47.441 million the same period last year.
Spero Therapeutics（纳斯达克股票代码：SPRO）公布的季度收益为每股0.96美元，比分析师普遍预期的0.10美元（0.10美元）高出1060％。这比去年同期每股收益0.55美元增长了74.55％。该公司公布的季度销售额为7352.4万美元，比分析师共识估计的1863.3万美元高出294.58％。这比去年同期的474.41万美元的销售额增长了54.98％。